HC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price Target

HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals (NASDAQ:INO) in a research report released on Wednesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the stock. Maxim Group dropped their price objective on shares of Inovio Pharmaceuticals from $12.00 to $8.00 and set a buy rating for the company in a research report on Thursday, February 15th. BidaskClub raised shares of Inovio Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, January 24th. ValuEngine lowered shares of Inovio Pharmaceuticals from a sell rating to a strong sell rating in a research report on Thursday, March 1st. Finally, Royal Bank of Canada increased their price objective on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the stock an outperform rating in a research report on Thursday, March 15th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $11.59.

Inovio Pharmaceuticals opened at $4.99 on Wednesday, Marketbeat.com reports. Inovio Pharmaceuticals has a 52-week low of $3.76 and a 52-week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.22). Inovio Pharmaceuticals had a negative return on equity of 72.04% and a negative net margin of 292.06%. The business had revenue of $1.53 million during the quarter, compared to analyst estimates of $7.50 million. During the same period in the previous year, the company earned ($0.31) EPS. analysts forecast that Inovio Pharmaceuticals will post -1.36 EPS for the current fiscal year.

In related news, Director David B. Weiner sold 9,000 shares of the firm’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $4.91, for a total transaction of $44,190.00. Following the completion of the sale, the director now directly owns 758,956 shares of the company’s stock, valued at approximately $3,726,473.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jong Joseph Kim sold 103,750 shares of the firm’s stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $5.14, for a total transaction of $533,275.00. Following the sale, the chief executive officer now directly owns 2,395,557 shares of the company’s stock, valued at $12,313,162.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 116,500 shares of company stock valued at $597,078. Company insiders own 9.40% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Guggenheim Capital LLC acquired a new stake in Inovio Pharmaceuticals during the 1st quarter valued at $2,375,000. UBS Group AG grew its holdings in Inovio Pharmaceuticals by 156.7% during the 1st quarter. UBS Group AG now owns 442,893 shares of the biopharmaceutical company’s stock valued at $2,086,000 after purchasing an additional 270,373 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Inovio Pharmaceuticals by 14.3% during the 1st quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock worth $689,000 after acquiring an additional 18,300 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Inovio Pharmaceuticals by 23.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 412,279 shares of the biopharmaceutical company’s stock worth $1,942,000 after acquiring an additional 77,277 shares in the last quarter. Finally, Swiss National Bank grew its holdings in Inovio Pharmaceuticals by 12.8% during the 1st quarter. Swiss National Bank now owns 156,400 shares of the biopharmaceutical company’s stock worth $737,000 after acquiring an additional 17,700 shares in the last quarter. 31.34% of the stock is owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply